As the patent of Crestor expires, the hyperlipidemia treatment market is expected to be more competitive

As the patent of Crestor expires, the hyperlipidemia treatment market is expected to be more competitive.

It was identified that prescription amount of hyperlipidemia treatment in May is similar to the previous year. Pfizer's 'Lipitor' recorded prescription amount of 8.2 billion won and firmly maintained the market leader position. 'Crestor' showed prescription amount of 6.3 billion won which ...